XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:      
Net loss $ (1,791) $ (4,377) $ (5,971)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization   70 74
Amortization of debt issuance costs 18 31 34
Amortization of debt discount 228 352 536
Change in the fair value of the derivative liability 112 (2,209) (135)
Change in the fair value of the warrant liability (1)   (33)
Change in the fair value of the Simple Agreements for Future Equity   1,976  
(Gain) loss on debt extinguishment   (443) 129
Equity-based compensation   264 342
Changes in operating assets and liabilities:      
Grant receivables   (283) 11
Prepaid expenses and other current assets   (18) (214)
Other receivables   264 966
Accounts payable   (278) 286
Accrued expenses and interest   258 275
Other current liabilities   661 747
Net cash used in operating activities   (3,732) (2,953)
Cash flows from investing activities:      
Payments for property and equipment     (10)
Net cash used in investing activities     (10)
Cash flows from financing activities:      
Payments on capital lease obligation     (4)
Proceeds from issuance of Simple Agreements for Future Equity   8,942  
Proceeds from the exercise of stock warrants   34 34
Proceeds from the exercise of stock options   19 11
Proceeds from the issuance of convertible notes     5,372
Deferred offering costs   (2,155)  
Debt issuance costs related to convertible notes     (93)
Net cash provided by financing activities   6,840 5,320
Effect of exchange rate changes on cash and cash equivalents   13 (4)
Net increase in cash and cash equivalents   3,121 2,353
Cash and cash equivalents      
Cash and cash equivalents-beginning of period   5,189 2,890
Cash and cash equivalents-end of period $ 5,243 8,310 5,243
Supplemental disclosures of non-cash financing activities:      
Non-cash accretion of convertible preferred stock to redemption value     $ 2,443
Deferred offering costs included in accounts payable   1,055  
Issuance of Series B-1 Convertible Preferred Stock upon conversion of debt   $ 29,391